Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Nanalysis Scientific Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Nanalysis Scientific's earnings have been declining at an average annual rate of -50.2%, while the Medical Equipment industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 33.6% per year.
Anahtar bilgiler
-50.2%
Kazanç büyüme oranı
-39.7%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | -19.2% |
| Gelir büyüme oranı | 33.6% |
| Özkaynak getirisi | -53.5% |
| Net Marj | -32.7% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 19
Nanalysis Scientific Corp. (CVE:NSCI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 12Benign Growth For Nanalysis Scientific Corp. (CVE:NSCI) Underpins Stock's 25% Plummet
Mar 24Nanalysis Scientific Corp. (CVE:NSCI) Shares Fly 43% But Investors Aren't Buying For Growth
Feb 08We Think Nanalysis Scientific (CVE:NSCI) Has A Fair Chunk Of Debt
Jan 31Would Nanalysis Scientific (CVE:NSCI) Be Better Off With Less Debt?
Aug 26Nanalysis Scientific Corp.'s (CVE:NSCI) Price Is Right But Growth Is Lacking
Apr 17Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?
Dec 08Is Nanalysis Scientific (CVE:NSCI) Weighed On By Its Debt Load?
Jul 15Health Check: How Prudently Does Nanalysis Scientific (CVE:NSCI) Use Debt?
Jan 24Is Nanalysis Scientific (CVE:NSCI) Using Debt Sensibly?
Mar 29Nanalysis Scientific (CVE:NSCI) Has Debt But No Earnings; Should You Worry?
Dec 14
Gelir ve Gider Dağılımı
Nanalysis Scientific nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 39 | -13 | 12 | 0 |
| 31 Mar 24 | 35 | -15 | 12 | 0 |
| 31 Dec 23 | 28 | -16 | 12 | 1 |
| 30 Sep 23 | 26 | -17 | 14 | 1 |
| 30 Jun 23 | 26 | -13 | 14 | 1 |
| 31 Mar 23 | 24 | -12 | 15 | 2 |
| 31 Dec 22 | 25 | -9 | 14 | 1 |
| 30 Sep 22 | 23 | -7 | 13 | 1 |
| 30 Jun 22 | 19 | -5 | 12 | 1 |
| 31 Mar 22 | 18 | -3 | 10 | 1 |
| 31 Dec 21 | 16 | -2 | 8 | 1 |
| 30 Sep 21 | 14 | -2 | 8 | 1 |
| 30 Jun 21 | 12 | -2 | 7 | 1 |
| 31 Mar 21 | 10 | -3 | 7 | 1 |
| 31 Dec 20 | 8 | -4 | 7 | 0 |
| 30 Sep 20 | 7 | -2 | 6 | 0 |
| 30 Jun 20 | 7 | -2 | 6 | 0 |
| 31 Mar 20 | 8 | -2 | 6 | 0 |
| 31 Dec 19 | 8 | -2 | 5 | 0 |
| 30 Sep 19 | 9 | -1 | 5 | 0 |
| 30 Jun 19 | 9 | -1 | 5 | 0 |
| 31 Mar 19 | 9 | 0 | 5 | 0 |
| 31 Dec 18 | 8 | 0 | 5 | 0 |
| 31 Dec 17 | 8 | 1 | 3 | 0 |
| 31 Dec 16 | 5 | 0 | 3 | 0 |
Kaliteli Kazançlar: NSCI is currently unprofitable.
Büyüyen Kar Marjı: NSCI is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: NSCI is unprofitable, and losses have increased over the past 5 years at a rate of 50.2% per year.
Büyüme Hızlandırma: Unable to compare NSCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: NSCI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.9%).
Özkaynak Getirisi
Yüksek ROE: NSCI has a negative Return on Equity (-53.49%), as it is currently unprofitable.